Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388

December 1, 2022

https://www.globenewswire.com/news-release/2022/12/01/2565884/0/en/Cidara-Therapeutics-Announces-Issuance-of-First-U-S-Patent-for-CD388.html

SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 11,510,992, entitled Compositions and Methods for the Treatment of Viral Infections, for CD388, a highly potent, long-acting drug-Fc conjugate (DFC) designed to achieve universal prevention of seasonal and pandemic influenza.

Read more at globenewswire.com

Related news for (CDTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.